SymBio suspends enrollment in Phase III of Ionsys

By Alicia Parker | May 26, 2017 | 5:46 PM GMT

SymBio Pharmaceuticals Ltd. (JASDAQ:4582) suspended enrollment in a Japanese Phase III trial of SyB P-1501 to manage acute postoperative pain during hospitalization after partner The Medicines Co. (NASDAQ:MDCO) said it intended

Read the full 311 word article

How to gain access

Continue reading with a
two-week free trial.